Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Verrica Pharmaceuticals Inc., a dermatology therapeutics company, develops and commercializes treatments for people with skin diseases in the United States. The company's lead product candidate includes VP-102 for the treatment of molluscum contagiosum; that has completed Phase II clinical trial for the treatment of external genital warts; and which is in Phase II clinical trial for treating common warts. It is also developing cantharidin-based product candidate, VP-103 for treating plantar warts. The company has a license and collaboration agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize LTX-315 for dermatological oncology indications. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.

Verrica Pharmaceuticals Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

WEST CHESTER, PA., JULY 30, 2026 (GLOBE NEWSWIRE) -- VERRICA PHARMACEUTICALS INC. (VERRICA OR THE COMPANY) (NASDAQ: VRCA), A THERAPEUTICS COMPANY DEVELOPING AND COMMERCIALIZING MEDICATIONS FOR THE TREATMENT OF DERMATOLOGICAL DISEASES, INCLUDING SKIN CANCERS, TODAY ANNOUNCED THAT IT WILL HOST A CONFERENCE CALL AND LIVE WEBCAST AT 4:30 P.M.

VERRICA PHARMACEUTICALS TO REPORT SECOND QUARTER 2026 FINANCIAL RESULTS AND PROVIDE A CORPORATE UPDATE ON AUGUST 6, 2026

WEST CHESTER, PA., JULY 21, 2026 (GLOBE NEWSWIRE) -- VERRICA PHARMACEUTICALS INC. (VERRICA) (NASDAQ: VRCA), A THERAPEUTICS COMPANY DEVELOPING AND COMMERCIALIZING MEDICATIONS FOR THE TREATMENT OF DERMATOLOGICAL DISEASES, INCLUDING SKIN CANCERS, TODAY ANNOUNCED AN EXCLUSIVE DISTRIBUTION, MARKETING AND SUPPLY AGREEMENT (THE AGREEMENT) GRANTING MEDOMIE PHARMA LTD.

VERRICA PHARMACEUTICALS AND MEDOMIE PHARMA ENTER INTO EXCLUSIVE DISTRIBUTION, MARKETING AND SUPPLY AGREEMENT TO COMMERCIALIZE YCANTH FOR THE TREATMENT OF MOLLUSCUM CONTAGIOSUM IN ISRAEL

 DEVELOPMENT PARTNER TORII PHARMACEUTICAL ALSO RECENTLY ANNOUNCED DOSING OF THE FIRST JAPANESE PATIENT IN THIS TRIAL EVALUATING YCANTH (TO-208) IN JAPAN 

VERRICA PHARMACEUTICALS ANNOUNCES FIRST U.S. PATIENT DOSED IN THE SECOND PIVOTAL CLINICAL TRIAL (COVE-3) OF ITS PHASE 3 PROGRAM EVALUATING YCANTH (VP-102) FOR THE TREATMENT OF COMMON WARTS

WEST CHESTER, PA., MAY 28, 2026 (GLOBE NEWSWIRE) -- VERRICA PHARMACEUTICALS INC. (VERRICA) (NASDAQ: VRCA), A THERAPEUTICS COMPANY DEVELOPING AND COMMERCIALIZING MEDICATIONS FOR THE TREATMENT OF DERMATOLOGICAL DISEASES, INCLUDING SKIN CANCERS, TODAY ANNOUNCED THAT JAYSON RIEGER, PHD, MBA, PRESIDENT AND CHIEF EXECUTIVE OFFICER OF VERRICA PHARMACEUTICALS, WILL PRESENT AT THE JEFFERIES GLOBAL HEALTHCARE CONFERENCE.

VERRICA PHARMACEUTICALS TO PARTICIPATE IN THE JEFFERIES GLOBAL HEALTHCARE CONFERENCE

WEST CHESTER, PA., MAY 13, 2026 (GLOBE NEWSWIRE) -- VERRICA PHARMACEUTICALS INC. (VERRICA) (NASDAQ: VRCA), A THERAPEUTICS COMPANY DEVELOPING AND COMMERCIALIZING MEDICATIONS FOR THE TREATMENT OF DERMATOLOGICAL DISEASES, INCLUDING SKIN CANCERS, TODAY ANNOUNCED THAT JAYSON RIEGER, PHD, MBA, PRESIDENT AND CHIEF EXECUTIVE OFFICER OF VERRICA PHARMACEUTICALS, WILL PRESENT AT THE H.C. WAINWRIGHT 4TH ANNUAL BIOCONNECT INVESTOR CONFERENCE AT NASDAQ.

VERRICA PHARMACEUTICALS TO PARTICIPATE IN THE H.C. WAINWRIGHT 4TH ANNUAL BIOCONNECT INVESTOR CONFERENCE AT NASDAQ

 COMPANY REPORTS RECORD DEMAND FOR YCANTH AS DISPENSED APPLICATOR UNITS GREW TO 15,302 IN Q1 2026, UP 12.1% OVER THE PREVIOUS QUARTER AND 51.3% YEAR-OVER-YEAR, AND HAS NOW EXCEEDED 100,000 DISPENSED APPLICATOR UNITS SINCE LAUNCH   COMPANY ANNOUNCES ACHIEVEMENT OF OVER 50% OF CURRENT TARGETED ENROLLMENT IN THE FIRST TRIAL IN GLOBAL PHASE 3 COMMON WARTS PROGRAM AND EXPECTS TO INITIATE THE SECOND TRIAL IN THE US AND JAPAN IN MID-2026  COMPANY REPORTS TOTAL REVENUE OF $5.0 MILLION IN Q1 2026, INCLUDING U.S. YCANTH NET PRODUCT REVENUE OF $4.3 MILLION IN Q1 2026, UP 16.2% OVER PREVIOUS QUARTER AND 25.4% YEAR-OVER-YEAR  YCANTH COMMERCIAL LAUNCH IN JAPAN BY PARTNER TORII PHARMACEUTICAL REPRESENTS EXPANSION INTO FIRST EX-U.S. MARKET  COMPANY CONTINUES PREPARATION FOR PHASE 3 STUDY OF VP-315 IN BASAL CELL CARCINOMA  CONFERENCE CALL SCHEDULED FOR TODAY, MAY 12, 2026, AT 4:30 PM ET WEST CHESTER, PA., MAY 12, 2026 (GLOBE NEWSWIRE) -- VERRICA PHARMACEUTICALS INC. (VERRICA) (NASDAQ: VRCA), A THERAPEUTICS COMPANY DEVELOPING AND COMMERCIALIZING MEDICATIONS FOR THE TREATMENT OF DERMATOLOGICAL DISEASES, INCLUDING SKIN CANCERS, TODAY ANNOUNCED FINANCIAL RESULTS FOR THE FIRST QUARTER ENDED MARCH 31, 2026.

VERRICA PHARMACEUTICALS REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS

PHASE 2 DATA HIGHLIGHT THE OBSERVED ABSCOPAL-LIKE EFFECT OF VP-315 IN NON-TREATED BASAL CELL CARCINOMA TUMORS WEST CHESTER, PA., MAY 05, 2026 (GLOBE NEWSWIRE) -- VERRICA PHARMACEUTICALS INC. (VERRICA) (NASDAQ: VRCA), A THERAPEUTICS COMPANY DEVELOPING AND COMMERCIALIZING MEDICATIONS FOR THE TREATMENT OF DERMATOLOGICAL DISEASES, INCLUDING SKIN CANCERS, TODAY ANNOUNCED THE PRESENTATION OF PHASE 2 CLINICAL DATA HIGHLIGHTING THE POTENTIAL ABSCOPAL EFFECTS OF THE COMPANY'S NOVEL ONCOLYTIC PEPTIDE, VP-315 (RUXOTEMITIDE), IN THE TREATMENT OF BASAL CELL CARCINOMA (BCC) AT THE 2026 SOCIETY FOR INVESTIGATIVE DERMATOLOGY (SID) ANNUAL MEETING, TAKING PLACE FROM MAY 13-16, 2026, IN CHICAGO, ILLINOIS.

VERRICA PHARMACEUTICALS ANNOUNCES UPCOMING PRESENTATION OF PHASE 2 DATA HIGHLIGHTING THE POTENTIAL ABSCOPAL EFFECTS OF VP-315 IN THE TREATMENT OF BASAL CELL CARCINOMA AT THE 2026 SOCIETY FOR INVESTIGATIVE DERMATOLOGY (SID) ANNUAL MEETING

WEST CHESTER, PA., MAY 05, 2026 (GLOBE NEWSWIRE) -- VERRICA PHARMACEUTICALS INC. (VERRICA OR THE COMPANY) (NASDAQ: VRCA), A THERAPEUTICS COMPANY DEVELOPING AND COMMERCIALIZING MEDICATIONS FOR THE TREATMENT OF DERMATOLOGICAL DISEASES, INCLUDING SKIN CANCERS, TODAY ANNOUNCED THAT IT WILL HOST A CONFERENCE CALL AND LIVE WEBCAST AT 4:30 P.M.

VERRICA PHARMACEUTICALS TO REPORT FIRST QUARTER 2026 FINANCIAL RESULTS AND PROVIDE A CORPORATE UPDATE ON MAY 12, 2026

WEST CHESTER, PA., APRIL 09, 2026 (GLOBE NEWSWIRE) -- VERRICA PHARMACEUTICALS INC. (VERRICA) (NASDAQ: VRCA), A THERAPEUTICS COMPANY DEVELOPING AND COMMERCIALIZING MEDICATIONS FOR THE TREATMENT OF DERMATOLOGICAL DISEASES, INCLUDING SKIN CANCERS, TODAY ANNOUNCED ACCEPTANCE OF A LATE-BREAKING ABSTRACT REPORTING PHASE 2 EXPLORATORY DATA OF VP-315, VERRICA'S NOVEL ONCOLYTIC PEPTIDE FOR THE TREATMENT OF BASAL CELL CARCINOMA.

VERRICA PHARMACEUTICALS ANNOUNCES ACCEPTANCE OF LATE-BREAKING ABSTRACT HIGHLIGHTING POTENTIAL ABSCOPAL EFFECT OF VP-315 FOR THE TREATMENT OF BASAL CELL CARCINOMA AT THE UPCOMING 2026 SOCIETY FOR INVESTIGATIVE DERMATOLOGY ANNUAL MEETING

WEST CHESTER, PA., APRIL 06, 2026 (GLOBE NEWSWIRE) -- VERRICA PHARMACEUTICALS INC. (VERRICA) (NASDAQ: VRCA), A THERAPEUTICS COMPANY DEVELOPING AND COMMERCIALIZING MEDICATIONS FOR THE TREATMENT OF DERMATOLOGICAL DISEASES, INCLUDING SKIN CANCERS, TODAY ANNOUNCED THAT JAYSON RIEGER, PHD, MBA, PRESIDENT AND CHIEF EXECUTIVE OFFICER OF VERRICA PHARMACEUTICALS, WILL PRESENT AT THE 25TH ANNUAL NEEDHAM VIRTUAL HEALTHCARE CONFERENCE.

Verrica Pharmaceuticals Inc.

VRCA

Price

Financial Reports

No items found.

Press Releases

Verrica Pharmaceuticals Inc.

VRCA.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

VRCA